Cargando…

Enhanced Potency and Durability of Antibody Response to Seasonal Trivalent Inactivated Influenza Vaccine (TIV) Combined with a Novel Water-in-Oil Adjuvant System at Reduced Hemagglutinin (HA) Doses

BACKGROUND: New influenza vaccines are needed to increase vaccine efficacy against infection and illness. Adjuvants may allow HA dose-sparing while increasing the antibody response. MAS-1 is an investigational low viscosity, free-flowing, water-in-oil emulsion-based adjuvant delivery system with sta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gorse, Geoffrey J, Grimes, Stephen, Buck, Helen, Mulla, Hussain, White, Peter, Graham, Irene, Treanor, John J, Hill, Heather, May, Jeanine, Blackburn, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631365/ http://dx.doi.org/10.1093/ofid/ofx163.1159

Ejemplares similares

Comparison of Serum Hemagglutinin and Neuraminidase Inhibition Antibodies After 2010–2011 Trivalent Inactivated Influenza Vaccination in Healthcare Personnel
por: Laguio-Vila, Maryrose R., et al.
Publicado: (2014)

Hemagglutinin Quantitative ELISA-based Potency Assay for Trivalent Seasonal Influenza Vaccine Using Group-Specific Universal Monoclonal Antibodies
por: Chae, Wonil, et al.
Publicado: (2019)

Broad cross-reactive IgG responses elicited by adjuvanted vaccination with recombinant influenza hemagglutinin (rHA) in ferrets and mice
por: Wang, Jiong, et al.
Publicado: (2018)

Strain-independent inactivated influenza vaccine production by removal of the hemagglutinin heavy HA1 chain
Publicado: (1986)

Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial
por: Carter, Cristina, et al.
Publicado: (2019)

Quillaja brasiliensis nanoparticle adjuvant formulation improves the efficacy of an inactivated trivalent influenza vaccine in mice
por: Silveira, Fernando, et al.
Publicado: (2023)

Cost-effectiveness analysis of intranasal live attenuated vaccine (LAIV) versus injectable inactivated influenza vaccine (TIV) for Canadian children and adolescents
por: Tarride, Jean-Eric, et al.
Publicado: (2012)

Enhanced Inhibition of Influenza A Virus Adhesion by Di- and Trivalent Hemagglutinin Inhibitors
por: Lu, Wenjing, et al.
Publicado: (2019)

Influenza symptoms and their impact on elderly adults: randomised trial of AS03-adjuvanted or non-adjuvanted inactivated trivalent seasonal influenza vaccines
por: van Essen, Gerrit A, et al.
Publicado: (2014)

Hemagglutinin Stalk Antibody Responses Following Trivalent Inactivated Influenza Vaccine Immunization of Pregnant Women and Association With Protection From Influenza Virus Illness
por: Dhar, Nisha, et al.
Publicado: (2020)

LOCALIZATION OF DNA AND PROTEIN IN TIPULA IRIDESCENT VIRUS (TIV) BY ENZYMATIC DIGESTION AND ELECTRON MICROSCOPY
por: Thomas, Richard S., et al.
Publicado: (1961)

Safety, Reactogenicity, and Health-Related Quality of Life After Trivalent Adjuvanted vs Trivalent High-Dose Inactivated Influenza Vaccines in Older Adults: A Randomized Clinical Trial
por: Schmader, Kenneth E., et al.
Publicado: (2021)

FluBlok, a recombinant hemagglutinin influenza vaccine
por: Cox, Manon M.J., et al.
Publicado: (2008)

Hemagglutinin stem reactive antibody response in individuals immunized with a seasonal influenza trivalent vaccine
por: Zhao, Xiaopeng, et al.
Publicado: (2015)

TIV Vaccination Modulates Host Responses to Influenza Virus Infection that Correlate with Protection against Bacterial Superinfection
por: Choi, Angela, et al.
Publicado: (2019)

Enhancing breadth and durability of humoral immune responses in non-human primates with an adjuvanted group 1 influenza hemagglutinin stem antigen
por: Swart, Maarten, et al.
Publicado: (2023)

Immunogenicity and safety of Quadrivalent Influenza HA vaccine compared with Trivalent Influenza HA vaccine and evaluation of Quadrivalent Influenza HA vaccine batch-to-batch consistency in Indonesian children and adults
por: Fadlyana, Eddy, et al.
Publicado: (2023)

Immunogenicity of AS03-adjuvanted and non-adjuvanted trivalent inactivated influenza vaccines in elderly adults: A Phase 3, randomized trial and post-hoc correlate of protection analysis
por: Ruiz-Palacios, Guillermo M., et al.
Publicado: (2016)

Immunogenicity and clinical effectiveness of the trivalent inactivated influenza vaccine in immunocompromised children undergoing treatment for cancer
por: Kotecha, Rishi S., et al.
Publicado: (2015)

Improvement of the Trivalent Inactivated Flu Vaccine Using PapMV Nanoparticles
por: Savard, Christian, et al.
Publicado: (2011)

Tolerability of trivalent inactivated influenza vaccine among pregnant women, 2015
por: Asavapiriyanont, Suvanna, et al.
Publicado: (2018)

Immunity Induced by Inactivated SARS-CoV-2 Vaccine: Breadth, Durability, Potency, and Specificity in a Healthcare Worker Cohort
por: Chen, Ying, et al.
Publicado: (2023)

Adjuvants and Immunization Strategies to Induce Influenza Virus Hemagglutinin Stalk Antibodies
por: Goff, Peter H., et al.
Publicado: (2013)

Recombinant hemagglutinin of swine H1N1 influenza virus expression in the insect cells: Formulation in Montanide ISA71 adjuvant and the potency studies
por: Zahmati, Sara, et al.
Publicado: (2021)

The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults
por: Ambrose, Christopher S., et al.
Publicado: (2010)

Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China
por: Mo, Zhaojun, et al.
Publicado: (2017)

Transcutaneous delivery and thermostability of a dry trivalent inactivated influenza vaccine patch
por: Frolov, Vladimir G., et al.
Publicado: (2008)

Impact of diabetes status on immunogenicity of trivalent inactivated influenza vaccine in older adults
por: Spencer, Sarah, et al.
Publicado: (2021)

Intestinal Immunity to Poliovirus Following Sequential Trivalent Inactivated Polio Vaccine/Bivalent Oral Polio Vaccine and Trivalent Inactivated Polio Vaccine–only Immunization Schedules: Analysis of an Open-label, Randomized, Controlled Trial in Chilean Infants
por: Brickley, Elizabeth B, et al.
Publicado: (2018)

Tuning aminopolycarboxylate chelators for efficient complexation of trivalent actinides
por: Pilgrim, Corey D., et al.
Publicado: (2023)

Assessment of in vitro potency of inactivated Newcastle disease oil-adjuvanted vaccines using hemagglutination test and blocking ELISA
por: Aly, Saleh E., et al.
Publicado: (2018)

Potency under pressure: the impact of hydrostatic pressure on antigenic properties of influenza virus hemagglutinin
por: Eichelberger, Schafer L., et al.
Publicado: (2013)

Relative Effectiveness of Adjuvanted Trivalent Inactivated Influenza Vaccine Versus Egg-derived Quadrivalent Inactivated Influenza Vaccines and High-dose Trivalent Influenza Vaccine in Preventing Influenza-related Medical Encounters in US Adults ≥ 65 Years During the 2017–2018 and 2018–2019 Influenza Seasons
por: Boikos, Constantina, et al.
Publicado: (2021)

A phase 1, open-label safety and immunogenicity study of an AS03-adjuvanted trivalent inactivated influenza vaccine in children aged 6 to 35 months
por: Carmona Martinez, Alfonso, et al.
Publicado: (2014)

Effects of Laser Texture Oxidation and High-Temperature Annealing of TiV Alloy Thin Films on Mechanical and Antibacterial Properties and Cytotoxicity
por: Chang, Yin-Yu, et al.
Publicado: (2018)

Quantification of trivalent non-replicating rotavirus vaccine antigens in the presence of aluminum adjuvant
por: McAdams, David, et al.
Publicado: (2021)

PapMV nanoparticles improve mucosal immune responses to the trivalent inactivated flu vaccine
por: Rioux, Gervais, et al.
Publicado: (2014)

Cost Effectiveness of Quadrivalent Versus Trivalent Inactivated Influenza Vaccines for the Portuguese Elderly Population
por: Tavares, Diana, et al.
Publicado: (2022)

Safety and tolerability of a 2009 trivalent inactivated split‐virion influenza vaccine in infants, children and adolescents
por: Lambert, Stephen B., et al.
Publicado: (2013)

Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)
por: Gelsomino, Francesco, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9b78615c5dd31m2pk6s67d4srh